GNA Biosolutions to Showcase PCA Technology for Ultrafast PCR and Pharos V8 instrument at Analytica 2018
Pharos V8 Laser PCR Instrument
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
GNA Biosolutions GmbH will be showcasing the Pharos V8, the world’s first Laser PCR instrument based on the company’s proprietary Pulse Controlled Amplification (PCA) technology at the Analytica trade fair (Booth A3/522) in Munich, Germany from April 10-13. Launched in November 2017, the Pharos V8 delivers ultrafast PCR results in 10 minutes or less.
Conventional PCR platforms rely on bulky thermocyclers that limit the speed of the reaction. The Pharos V8 is the world’s first Laser PCR instrument powered by PCA, a novel patented technology developed by GNA Biosolutions.
Key features of PCA:
• Unique patented technology for ultrafast nucleic acid amplification
• Utilizes microcyclers in solution as miniature thermal hubs for the PCR reaction
• Rapid energy pulses control speed, resulting in ultrafast PCR reaction times
Key features of the Pharos V8:
• First commercially available Laser PCR instrument, based on PCA technology
• Ultrafast PCR results in 10 minutes or less, on an easy to use interface
• Universal DNA kit for lab-developed tests (bacterial, human genomic & viral DNA) in both single and multiplex formats
Lars Ullerich, Managing Director GNA Biosolutions states, "PCA is a completely unique and exciting approach to PCR that takes something fundamental and pushes it further. The Pharos V8 instrument delivers results with high sensitivity and unparalleled speed and makes PCR even more useful; it creates new possibilities for a range of different applications across multiple industries."
In addition to the Pharos V8, GNA Biosolutions is implementing Laser PCR in an integrated sample-preparation system, as part of a consortium focused on MRSA detection (KAREL). The company also recently completed successful Laser PCR field tests for Ebola RNA virus detection in Sierra Leone as part of a publicly funded project (FILODIAG).
Conventional PCR platforms rely on bulky thermocyclers that limit the speed of the reaction. The Pharos V8 is the world’s first Laser PCR instrument powered by PCA, a novel patented technology developed by GNA Biosolutions.
Key features of PCA:
• Unique patented technology for ultrafast nucleic acid amplification
• Utilizes microcyclers in solution as miniature thermal hubs for the PCR reaction
• Rapid energy pulses control speed, resulting in ultrafast PCR reaction times
Key features of the Pharos V8:
• First commercially available Laser PCR instrument, based on PCA technology
• Ultrafast PCR results in 10 minutes or less, on an easy to use interface
• Universal DNA kit for lab-developed tests (bacterial, human genomic & viral DNA) in both single and multiplex formats
Lars Ullerich, Managing Director GNA Biosolutions states, "PCA is a completely unique and exciting approach to PCR that takes something fundamental and pushes it further. The Pharos V8 instrument delivers results with high sensitivity and unparalleled speed and makes PCR even more useful; it creates new possibilities for a range of different applications across multiple industries."
In addition to the Pharos V8, GNA Biosolutions is implementing Laser PCR in an integrated sample-preparation system, as part of a consortium focused on MRSA detection (KAREL). The company also recently completed successful Laser PCR field tests for Ebola RNA virus detection in Sierra Leone as part of a publicly funded project (FILODIAG).
